A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the safety and CSF penetration of combined ganciclovir and foscarnet treatment
for presumed cytomegalovirus encephalitis or radiculomyelopathy.
This study proposes to investigate the use of combined ganciclovir and foscarnet to maximize
the antiviral regimen. Current evidence suggests that a combination of ganciclovir and
foscarnet may be the most efficacious therapy and appears to be well tolerated. This study
will provide key information regarding safety and CSF penetration of the drugs available for
treatment of these lethal diseases. It will also provide preliminary information regarding
virologic factors relevant to CMV CNS disease. The study will also provide further data about
the natural history of CMV brain infection detected by a combination of symptom complex and
PCR identification of CMV in CSF and the potential of semi-quantitative PCR evaluation of the
CSF for the disease.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)